Skip to content
DataLookout
Menu

NCT06642038

Efficacy and Safety of Transbronchial Bronchoscopic Thermal Vapor Ablation (BTVA) in Heterogeneous Emphysema

StatusUnknown
PhaseNot specified
SponsorYe Gu
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

The forced expiratory volume in one second (FEV1) is used to assess lung function
Timeframe: 6 months
The Saint George's Respiratory Questionnaire-C (SGRQ-C) questionnaire was used to evaluate the value of patients' quality of life.
Timeframe: 6 months

Secondary (9)

FEV1 is used to assess lung function
The SGRQ-C questionnaire was used to evaluate the value of patients' quality of life.
Forced expiratory volume in one second/Forced vital capcacity(FEV1/FVC) were used to assess lung function
FVC were used to assess lung function
ResidualVolume (RV) were used to assess lung function
Show 4 moreShow less
Total Lung Capacity(TLC) were used to assess lung function
6 minute walking distance (6MWD) was used to assess exercise tolerance
Symptom scoring using COPD Assessment Test (CAT), modified Medical Research Council (mMRC) scoring table
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Arms and interventions

Experimental Group

Procedures: Transbronchial Endoscopic Thermal Vapor Ablation